HC Wainwright reaffirmed their buy rating on shares of IceCure Medical (NASDAQ:ICCM - Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $2.50 target price on the stock.
IceCure Medical Stock Performance
Shares of ICCM stock traded up $0.08 during mid-day trading on Friday, hitting $1.19. 210,528 shares of the stock were exchanged, compared to its average volume of 520,720. The stock has a market capitalization of $65.77 million, a price-to-earnings ratio of -4.09 and a beta of 0.37. IceCure Medical has a 12-month low of $0.48 and a 12-month high of $1.66. The stock's fifty day simple moving average is $1.32 and its two-hundred day simple moving average is $0.99. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.27 and a current ratio of 2.67.
IceCure Medical (NASDAQ:ICCM - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The business had revenue of $1.07 million for the quarter, compared to analysts' expectations of $1.07 million. IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. On average, analysts forecast that IceCure Medical will post -0.28 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in IceCure Medical stock. XTX Topco Ltd grew its position in shares of IceCure Medical Ltd (NASDAQ:ICCM - Free Report) by 123.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 58,866 shares of the company's stock after buying an additional 32,555 shares during the period. XTX Topco Ltd owned about 0.11% of IceCure Medical worth $65,000 as of its most recent SEC filing. Institutional investors own 0.62% of the company's stock.
IceCure Medical Company Profile
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Further Reading
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
